Share Price and Basic Stock Data
Last Updated: December 12, 2025, 8:12 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Global Longlife Hospital and Research Ltd operates in the Hospitals and Medical Services sector, a critical industry that has seen fluctuating demand patterns, especially in the wake of global health crises. The company’s revenue trajectory has been quite erratic, with sales reported at ₹19.94 Cr in September 2021, but declining steadily to ₹11.70 Cr by March 2023. Most recently, sales picked up slightly to ₹12.33 Cr in September 2023, indicating a potential recovery phase. However, the trailing twelve months (TTM) figures reveal a stark drop to ₹0.31 Cr by March 2025, suggesting that while there may be short-term improvements, the longer-term trend is concerning. The decrease in revenue reflects broader challenges within the healthcare sector, including increased competition and changing patient expectations. The reliance on operational efficiency and service quality will be pivotal for the company to stabilize its revenue streams in this competitive landscape.
Profitability and Efficiency Metrics
Profitability for Global Longlife Hospital has been a mixed bag, with the operating profit margin (OPM) showcasing significant volatility. After peaking at 33.90% in September 2021, the OPM plummeted to negative figures, with a shocking -255.93% reported for March 2024. This drastic decline raises red flags about operational efficiency and cost management. However, the net profit margin stood at 34.41% for March 2025, a remarkable recovery compared to the previous year when it was -16.19%. This indicates that while the company has struggled with operating costs, its ability to generate net profit has seen a rebound, albeit from a low base. The interest coverage ratio of 3.10x suggests that the company can comfortably meet its interest obligations, but the high cash conversion cycle of 376.77 days indicates inefficiencies in converting sales into cash flow, posing a risk to liquidity.
Balance Sheet Strength and Financial Ratios
Examining the balance sheet, Global Longlife Hospital showcases a robust position with zero borrowings, reflecting a conservative financial strategy. The company’s reserves stood at ₹14.97 Cr, which provides a cushion against operational volatility. The return on equity (ROE) at 17.7% appears strong, indicating effective use of shareholder funds, while the return on capital employed (ROCE) at 13.7% suggests decent operational efficiency. However, the price-to-book value (P/BV) ratio of 0.74x indicates that the stock is trading below its book value, which may either signal undervaluation or concerns about future profitability. The current ratio of 405.69x raises eyebrows, suggesting either a substantial cash reserve or potential issues with asset management. Investors might want to probe deeper into the underlying causes of such a high ratio, as it could indicate inefficiencies that need addressing.
Shareholding Pattern and Investor Confidence
Investor sentiment appears stable, with promoters holding a significant 55.10% stake in Global Longlife Hospital as of September 2025. This level of promoter commitment can enhance confidence among retail investors, suggesting a strong belief in the company’s potential. The public shareholding stands at 44.91%, which, while lower than the promoter share, still indicates reasonable public interest. The number of shareholders has fluctuated, dropping to 915 from a previous high of 1,010, indicating a slight erosion in retail investor confidence, possibly due to the company’s inconsistent performance. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) might also raise concerns about the stock’s attractiveness to larger, more sophisticated investors, further complicating the narrative around its growth potential.
Outlook, Risks, and Final Insight
The outlook for Global Longlife Hospital is nuanced, with several risks and opportunities at play. While the recent uptick in net profitability is encouraging, the volatility in revenue and operational metrics paints a picture of uncertainty. The company must focus on enhancing operational efficiency to manage costs better and reduce the cash conversion cycle, which is currently a significant concern. Additionally, the healthcare sector’s evolving landscape demands that Global Longlife innovate and adapt to meet changing consumer expectations. Risks include potential regulatory changes that could impact operations and the ongoing challenge of competition within the healthcare sector. Investors should weigh these risks against the company’s strengths, such as its zero debt and strong promoter backing, when considering their investment choices. Overall, while there are reasons to be cautiously optimistic, the company must navigate these challenges effectively to realize its potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 43.2 Cr. | 129 | 195/120 | 8.83 | 117 | 2.71 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 22.0 Cr. | 21.0 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.00 Cr. | 8.70 | 20.8/8.66 | 100 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 115 Cr. | 61.3 | 98.7/55.2 | 25.4 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.1 Cr. | 3.72 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,323.57 Cr | 758.87 | 94.10 | 99.39 | 0.32% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Global Longlife Hospital and Research Ltd
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19.94 | 12.87 | 11.80 | 11.70 | 12.33 | 1.18 | 0.58 | 0.00 |
| Expenses | 13.18 | 11.61 | 10.03 | 9.44 | 9.62 | 4.20 | 4.39 | 0.35 |
| Operating Profit | 6.76 | 1.26 | 1.77 | 2.26 | 2.71 | -3.02 | -3.81 | -0.35 |
| OPM % | 33.90% | 9.79% | 15.00% | 19.32% | 21.98% | -255.93% | -656.90% | |
| Other Income | 0.07 | 0.16 | 0.07 | 0.17 | 0.02 | 0.04 | 5.69 | -0.67 |
| Interest | 0.09 | 1.31 | 0.20 | 0.20 | 0.41 | 0.36 | 0.28 | 0.00 |
| Depreciation | 0.58 | 0.57 | 0.58 | 0.59 | 0.61 | 0.64 | 0.48 | 0.00 |
| Profit before tax | 6.16 | -0.46 | 1.06 | 1.64 | 1.71 | -3.98 | 1.12 | -1.02 |
| Tax % | 0.00% | -78.26% | 29.25% | 35.37% | 39.77% | -19.10% | -11.61% | 2.94% |
| Net Profit | 6.17 | -0.10 | 0.76 | 1.07 | 1.03 | -3.22 | 1.24 | -1.04 |
| EPS in Rs | 8.81 | -0.14 | 0.72 | 1.02 | 0.98 | -3.07 | 1.18 | -0.99 |
Last Updated: May 31, 2025, 5:54 am
Below is a detailed analysis of the quarterly data for Global Longlife Hospital and Research Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.58 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.58 Cr..
- For Expenses, as of Mar 2025, the value is 0.35 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.39 Cr. (Sep 2024) to 0.35 Cr., marking a decrease of 4.04 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.35 Cr.. The value appears strong and on an upward trend. It has increased from -3.81 Cr. (Sep 2024) to -0.35 Cr., marking an increase of 3.46 Cr..
- For OPM %, as of Mar 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -656.90% (Sep 2024) to 0.00%, marking an increase of 656.90%.
- For Other Income, as of Mar 2025, the value is -0.67 Cr.. The value appears to be declining and may need further review. It has decreased from 5.69 Cr. (Sep 2024) to -0.67 Cr., marking a decrease of 6.36 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.28 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.28 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.48 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.48 Cr..
- For Profit before tax, as of Mar 2025, the value is -1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.12 Cr. (Sep 2024) to -1.02 Cr., marking a decrease of 2.14 Cr..
- For Tax %, as of Mar 2025, the value is 2.94%. The value appears to be increasing, which may not be favorable. It has increased from -11.61% (Sep 2024) to 2.94%, marking an increase of 14.55%.
- For Net Profit, as of Mar 2025, the value is -1.04 Cr.. The value appears to be declining and may need further review. It has decreased from 1.24 Cr. (Sep 2024) to -1.04 Cr., marking a decrease of 2.28 Cr..
- For EPS in Rs, as of Mar 2025, the value is -0.99. The value appears to be declining and may need further review. It has decreased from 1.18 (Sep 2024) to -0.99, marking a decrease of 2.17.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 1:02 pm
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 33.44 | 33.32 | 32.70 | 32.44 | 23.38 | 13.46 | 0.31 |
| Expenses | 26.61 | 29.88 | 27.26 | 24.14 | 19.30 | 13.68 | 4.45 |
| Operating Profit | 6.83 | 3.44 | 5.44 | 8.30 | 4.08 | -0.22 | -4.14 |
| OPM % | 20.42% | 10.32% | 16.64% | 25.59% | 17.45% | -1.63% | -1,335.48% |
| Other Income | 0.08 | 0.03 | 0.06 | 0.17 | 0.24 | 0.00 | 5.02 |
| Interest | 2.07 | 2.41 | 2.44 | 1.62 | 0.45 | 0.80 | 0.30 |
| Depreciation | 2.15 | 2.13 | 1.31 | 1.14 | 1.17 | 1.25 | 0.48 |
| Profit before tax | 2.69 | -1.07 | 1.75 | 5.71 | 2.70 | -2.27 | 0.10 |
| Tax % | 49.07% | -18.69% | -16.57% | 37.30% | 32.59% | -3.52% | -100.00% |
| Net Profit | 1.36 | -0.86 | 2.05 | 3.57 | 1.83 | -2.19 | 0.20 |
| EPS in Rs | 1.94 | -1.23 | 2.93 | 5.10 | 1.74 | -2.09 | 0.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -163.24% | 338.37% | 74.15% | -48.74% | -219.67% | 109.13% |
| Change in YoY Net Profit Growth (%) | 0.00% | 501.61% | -264.23% | -122.89% | -170.93% | 328.80% |
Global Longlife Hospital and Research Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -61% |
| 3 Years: | -79% |
| TTM: | -98% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -119% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -33% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | -4% |
| Last Year: | -18% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:57 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 10.50 | 10.50 | 10.50 | 10.50 |
| Reserves | 5.35 | 4.49 | 6.68 | 9.96 | 53.79 | 15.43 | 16.29 | 14.97 |
| Borrowings | 27.18 | 23.51 | 17.04 | 8.69 | 9.29 | 12.74 | 0.00 | 0.00 |
| Other Liabilities | 3.77 | 6.92 | 6.06 | 8.33 | 2.36 | 3.07 | 0.06 | 0.01 |
| Total Liabilities | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 | 25.48 |
| Fixed Assets | 20.17 | 18.72 | 17.46 | 16.71 | 16.52 | 17.27 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 1.03 | 0.00 | 0.00 | 0.00 |
| Investments | 0.10 | 0.10 | 0.47 | 0.10 | 0.10 | 0.03 | 0.03 | 0.00 |
| Other Assets | 23.03 | 23.10 | 18.85 | 17.17 | 58.29 | 24.44 | 26.82 | 25.48 |
| Total Assets | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 | 25.48 |
Below is a detailed analysis of the balance sheet data for Global Longlife Hospital and Research Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.50 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.50 Cr..
- For Reserves, as of Sep 2025, the value is 14.97 Cr.. The value appears to be declining and may need further review. It has decreased from 16.29 Cr. (Mar 2025) to 14.97 Cr., marking a decrease of 1.32 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing). It has decreased from 0.06 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.05 Cr..
- For Total Liabilities, as of Sep 2025, the value is 25.48 Cr.. The value appears to be improving (decreasing). It has decreased from 26.85 Cr. (Mar 2025) to 25.48 Cr., marking a decrease of 1.37 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.03 Cr..
- For Other Assets, as of Sep 2025, the value is 25.48 Cr.. The value appears to be declining and may need further review. It has decreased from 26.82 Cr. (Mar 2025) to 25.48 Cr., marking a decrease of 1.34 Cr..
- For Total Assets, as of Sep 2025, the value is 25.48 Cr.. The value appears to be declining and may need further review. It has decreased from 26.85 Cr. (Mar 2025) to 25.48 Cr., marking a decrease of 1.37 Cr..
Notably, the Reserves (14.97 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.35 | -20.07 | -11.60 | -0.39 | -5.21 | -12.96 | -4.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 94.85 | 68.68 | 87.51 | 100.25 | 151.43 | 52.88 | 376.77 |
| Inventory Days | 169.49 | 157.97 | 34.46 | 88.98 | 69.12 | 131.64 | 0.00 |
| Days Payable | 229.91 | 391.69 | 138.68 | 432.74 | 110.43 | 765.90 | |
| Cash Conversion Cycle | 34.44 | -165.03 | -16.71 | -243.52 | 110.13 | -581.38 | 376.77 |
| Working Capital Days | 19.21 | 12.16 | 7.14 | -29.70 | 344.86 | -238.36 | 1,283.39 |
| ROCE % | 3.81% | 12.75% | 26.22% | 6.35% | -2.51% | -13.69% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Diluted EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Cash EPS (Rs.) | 0.64 | -0.89 | 2.85 | 6.74 | 5.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Revenue From Operations / Share (Rs.) | 0.54 | 12.87 | 22.38 | 46.88 | 46.72 |
| PBDIT / Share (Rs.) | 0.81 | -0.23 | 4.07 | 11.79 | 8.67 |
| PBIT / Share (Rs.) | 0.35 | -1.43 | 2.96 | 10.15 | 5.98 |
| PBT / Share (Rs.) | 0.09 | -2.16 | 2.58 | 8.16 | 2.51 |
| Net Profit / Share (Rs.) | 0.18 | -2.08 | 1.74 | 5.11 | 2.92 |
| PBDIT Margin (%) | 148.50 | -1.83 | 18.18 | 25.14 | 18.56 |
| PBIT Margin (%) | 65.02 | -11.08 | 13.22 | 21.66 | 12.81 |
| PBT Margin (%) | 17.18 | -16.76 | 11.52 | 17.40 | 5.37 |
| Net Profit Margin (%) | 34.41 | -16.19 | 7.77 | 10.89 | 6.25 |
| Return on Networth / Equity (%) | 0.74 | -8.43 | 2.84 | 21.06 | 14.96 |
| Return on Capital Employeed (%) | 1.40 | -5.09 | 4.56 | 35.19 | 15.94 |
| Return On Assets (%) | 0.74 | -5.24 | 2.40 | 10.51 | 5.56 |
| Long Term Debt / Equity (X) | 0.00 | 0.13 | 0.05 | 0.16 | 0.91 |
| Total Debt / Equity (X) | 0.00 | 0.49 | 0.14 | 0.51 | 0.91 |
| Asset Turnover Ratio (%) | 0.01 | 0.22 | 0.42 | 0.92 | 0.85 |
| Current Ratio (X) | 405.69 | 0.31 | 4.28 | 0.82 | 1.13 |
| Quick Ratio (X) | 405.69 | 0.28 | 4.17 | 0.75 | 1.06 |
| Inventory Turnover Ratio (X) | 2.64 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.10 | -0.32 | 10.67 | 5.90 | 2.50 |
| Interest Coverage Ratio (Post Tax) (X) | 1.72 | -1.85 | 5.56 | 3.55 | 1.84 |
| Enterprise Value (Cr.) | -1.58 | 53.35 | 52.71 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | -2.74 | 3.95 | 2.24 | 0.00 | 0.00 |
| EV / EBITDA (X) | -1.85 | -215.57 | 12.33 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 34.48 | 3.03 | 2.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.74 | 1.58 | 0.73 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 34.54 | 3.03 | 2.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | -0.05 | 0.03 | 0.00 | 0.00 |
After reviewing the key financial ratios for Global Longlife Hospital and Research Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 3. It has increased from -0.89 (Mar 24) to 0.64, marking an increase of 1.53.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.54. It has decreased from 12.87 (Mar 24) to 0.54, marking a decrease of 12.33.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 2. It has increased from -0.23 (Mar 24) to 0.81, marking an increase of 1.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from -1.43 (Mar 24) to 0.35, marking an increase of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from -2.16 (Mar 24) to 0.09, marking an increase of 2.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has increased from -2.08 (Mar 24) to 0.18, marking an increase of 2.26.
- For PBDIT Margin (%), as of Mar 25, the value is 148.50. This value is within the healthy range. It has increased from -1.83 (Mar 24) to 148.50, marking an increase of 150.33.
- For PBIT Margin (%), as of Mar 25, the value is 65.02. This value exceeds the healthy maximum of 20. It has increased from -11.08 (Mar 24) to 65.02, marking an increase of 76.10.
- For PBT Margin (%), as of Mar 25, the value is 17.18. This value is within the healthy range. It has increased from -16.76 (Mar 24) to 17.18, marking an increase of 33.94.
- For Net Profit Margin (%), as of Mar 25, the value is 34.41. This value exceeds the healthy maximum of 10. It has increased from -16.19 (Mar 24) to 34.41, marking an increase of 50.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 15. It has increased from -8.43 (Mar 24) to 0.74, marking an increase of 9.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 10. It has increased from -5.09 (Mar 24) to 1.40, marking an increase of 6.49.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has increased from -5.24 (Mar 24) to 0.74, marking an increase of 5.98.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.00, marking a decrease of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.49 (Mar 24) to 0.00, marking a decrease of 0.49.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.22 (Mar 24) to 0.01, marking a decrease of 0.21.
- For Current Ratio (X), as of Mar 25, the value is 405.69. This value exceeds the healthy maximum of 3. It has increased from 0.31 (Mar 24) to 405.69, marking an increase of 405.38.
- For Quick Ratio (X), as of Mar 25, the value is 405.69. This value exceeds the healthy maximum of 2. It has increased from 0.28 (Mar 24) to 405.69, marking an increase of 405.41.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.64, marking an increase of 2.64.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.10. This value is within the healthy range. It has increased from -0.32 (Mar 24) to 3.10, marking an increase of 3.42.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 3. It has increased from -1.85 (Mar 24) to 1.72, marking an increase of 3.57.
- For Enterprise Value (Cr.), as of Mar 25, the value is -1.58. It has decreased from 53.35 (Mar 24) to -1.58, marking a decrease of 54.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is -2.74. This value is below the healthy minimum of 1. It has decreased from 3.95 (Mar 24) to -2.74, marking a decrease of 6.69.
- For EV / EBITDA (X), as of Mar 25, the value is -1.85. This value is below the healthy minimum of 5. It has increased from -215.57 (Mar 24) to -1.85, marking an increase of 213.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 34.48. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.48, marking an increase of 31.45.
- For Price / BV (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 1.58 (Mar 24) to 0.74, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 34.54. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.54, marking an increase of 31.51.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.01, marking an increase of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Global Longlife Hospital and Research Ltd:
- Net Profit Margin: 34.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.4% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.74% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 405.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 94.1)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 34.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad Gujarat 380059 | investor@globalhospital.co.in http://www.globalhospital.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dhruv Jani | Managing Director |
| Ms. Hetal Thakkar | Executive Director & CFO |
| Mrs. Sucheta Jani | Non Executive Director |
| Mr. Manasvi Thapar | Independent Director |
| Mr. Sandeep Shah | Independent Director |
FAQ
What is the intrinsic value of Global Longlife Hospital and Research Ltd?
Global Longlife Hospital and Research Ltd's intrinsic value (as of 12 December 2025) is 52.65 which is 150.71% higher the current market price of 21.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 22.0 Cr. market cap, FY2025-2026 high/low of 35.5/15.5, reserves of ₹14.97 Cr, and liabilities of 25.48 Cr.
What is the Market Cap of Global Longlife Hospital and Research Ltd?
The Market Cap of Global Longlife Hospital and Research Ltd is 22.0 Cr..
What is the current Stock Price of Global Longlife Hospital and Research Ltd as on 12 December 2025?
The current stock price of Global Longlife Hospital and Research Ltd as on 12 December 2025 is 21.0.
What is the High / Low of Global Longlife Hospital and Research Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Global Longlife Hospital and Research Ltd stocks is 35.5/15.5.
What is the Stock P/E of Global Longlife Hospital and Research Ltd?
The Stock P/E of Global Longlife Hospital and Research Ltd is .
What is the Book Value of Global Longlife Hospital and Research Ltd?
The Book Value of Global Longlife Hospital and Research Ltd is 24.3.
What is the Dividend Yield of Global Longlife Hospital and Research Ltd?
The Dividend Yield of Global Longlife Hospital and Research Ltd is 0.00 %.
What is the ROCE of Global Longlife Hospital and Research Ltd?
The ROCE of Global Longlife Hospital and Research Ltd is 13.7 %.
What is the ROE of Global Longlife Hospital and Research Ltd?
The ROE of Global Longlife Hospital and Research Ltd is 17.7 %.
What is the Face Value of Global Longlife Hospital and Research Ltd?
The Face Value of Global Longlife Hospital and Research Ltd is 10.0.